Sold as Synagis. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Palivizumab (sold as Synagis), first approved Jun 19, 1998, with 2 new uses approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) DiseaseRespiratory Syncytial Virus (RSV) · AstraZeneca | Not applicable | Active, not recruiting | Feb 28, 2025 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jun 19, 1998 | SynagisBLA 103770 · New molecular entity | Swedish Orphan | 10 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA